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Renal failure is increasingly being recognised in CF patients, usually as a consequence of long-term nephrotoxic therapy. There is a need
for a simple method of assessment of renal function in this patient group. We compared measured creatinine clearance from validated timed
urine collections (the generally accepted practical test of glomerular filtration) with 10 formulae used to estimate creatinine clearance in a
group of 74 CF adult patients and 29 matched normal controls. Compared to direct measurement, formulae gave a range of values (95% CI
for mean bias −13 to +27.9 ml/min). Even those with the best correlation (r=0.7) gave wide error ranges (limits of agreement: −42.3 to
45.9 ml/min). The most commonly used formulae (Cockroft–Gault [CGF] and abbreviated Modification of Diet in Renal Disease [aMDRD])
were not superior to most other formulae tested. Both CGF and aMDRD-derived estimates compared less favourably in CF patients than
controls (mean bias: 9.7 vs 3.4 ml/min (p<0.05) and 4.9 vs 1.4 (p<0.05) respectively; 78% vs 95% (p<0.01) and 77% vs 97% (p<0.01) of
estimates within 33% of measurement respectively). In particular, both CGF and aMDRD grossly overestimated renal function (mean bias
18.3 and 15.8 ml/min respectively, p<0.001) in CF patients with reduced creatinine clearance (<80 ml/min).
CGF, aMDRD and other formulae cannot be used to reliably assess renal function in CF patients, since they will fail to detect those with
renal impairment. Some form of carefully supervised direct measurement is still required.
© 2006 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Adults with cystic fibrosis; Accuracy; Measurement system1. Introduction
Although CFTR protein is expressed in the kidney, renal
disease is not a primary complication of the CF state [1].
Previously, renal stones were a recognised feature of
dehydration due to CF [2], and more recently cases of
acute renal failure have been reported in CF children [3,4].
We have now shown that acute renal failure can occur in CF
patients undergoing aminoglycoside therapy [5], and have
demonstrated an association between the cumulative life
time use of these nephrotoxic antibiotics and diminishing⁎ Corresponding author.
E-mail address: MWalshaw@doctors.org.uk (M. Walshaw).
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doi:10.1016/j.jcf.2006.05.004renal function in adult CF individuals [6]. With improving
survival, CF patients will become repeatedly exposed to
these renally harmful antibiotics in the treatment of
pulmonary exacerbations and careful monitoring of renal
function is therefore essential.
Renal function depends upon the glomerular filtration
rate, which is most easily reflected in clinical practice by the
ability of the kidney to clear the muscle breakdown product
creatinine (the creatinine clearance rate) [7]. Measurement of
this requires comparison of the urinary and serum creatinine,
which in turn depends upon an accurate assessment of
urinary creatinine, best provided by a 24-h urine collection
[7]. However, the need for timed urine collections can lead to
compliance errors in adults, and in children may not be
possible.ed by Elsevier B.V. All rights reserved.
42 M. Al-Aloul et al. / Journal of Cystic Fibrosis 6 (2007) 41–47To circumvent this, formulae [8–17] based on the serum
creatinine and physical characteristics of the subject have
been developed to estimate creatinine clearance. They are
commonly used in children and also where drug dosages
need to be adjusted according to renal function. Of these, the
Cockroft–Gault Formula (CGF) [8] and the abbreviated
MDRD [17] (aMDRD) are the most widely used in clinical
practice. The accuracy of CGF in different settings (e.g., the
elderly[18], diabetics [19] and patients with cancer [20]) has
been documented. CGF has recently been recommended for
use in CF patients [21] and the UK Chronic Kidney Disease
guidelines [22] advocate the use of aMDRD for automated
laboratory reporting of estimated glomerular filtration rate.
However, neither of the two formulae has been validated in
the CF population. To investigate this further, we compared
the accuracy of CGF, MDRD, aMDRD and other formulae
with measured creatinine clearance over a range of renal
function in a group of adult CF patients and also in a control
group of non-CF patients.
2. Patients
2.1. CF population
Eighty three adult CF patients (FEV1 % predicted: mean
63, S.D. 23, range 16–119) attending the outpatient clinic
were recruited between January 2002 and August 2004. All
patients had a serum creatinine within the normal range
(mean 85.5 μmol/l, standard deviation [S.D.] 15.8). None
had previous history of renal problems, including acute drug
related nephrotoxicity, and all were in a stable clinical state
with no acute antibiotic therapy for at least 12 weeks prior to
study. In addition, all had normal renal ultrasound scans at
annual screen.
2.2. Control population
The control group consisted of forty age and BMI
matched (Table 1) non-CF subjects attending the general
medical department for management of hypertension with
stable renal function and a serum creatinine within the
normal range (84.0 μmol/l [S.D. 13.5]). None had severe
hypertension, any evidence of end organ damage, or were
taking nephrotoxic drugs. Controls were selected if they had
at least one urine sample for estimation of GFR collected
during the same time interval mentioned above.Table 1
Baseline characteristics of the study population
CF patients Non-CF controls
N 83 40
M/F 44:39 26:14
Age (years) 24.3 (7.5) 26.2 (5.1)
BMI (kg/m2) 21.3 (3.6) 22.5 (4.3)
SCr (μmol/l) 85.5 (15.8) 84.0 (13.5)
Data presented as means (S.D.) where appropriate.3. Methods
3.1. Measured creatinine clearance (mCCl)
All subjects received routine instructions on how to
collect 24-h urine samples. CF patients submitted 206
urine collections (median 2 samples per patient; range 1–
5) compared with 82 collections from controls (median 2
per patient, range 1–3). Samples of less than 500 ml were
excluded. The mean urinary creatinine per kilogram body
weight was calculated separately for men (CF: 0.187 [S.D.
0.046] mmol/kg; controls: 0.181 [0.061 mmol/kg]) and
women (CF: 0.138 [0.040] mmol/kg; controls: 0.142
[0.044] mmol/kg). As previously described [6,23], all
24-h urine collections that had creatinine/kilogram within
one standard deviation of these respective means were
considered valid and included for further evaluation.
Following validation, 159 (77%) collections from 74 CF
patients and 60 (73%) from 29 controls were used to
obtain mCCl. Valid collections from each patient were
averaged to form single data points. SCr was measured
after an 8 h fast at the end of each collection by standard
autoanalyser technique. The clearance of endogenous
creatinine was determined by the formula mCCl=Urine
Cr⁎Urine volume/SCr and expressed as ml/min [7]. No
attempt was made to convert mCCl in terms of body
surface area (BSA).
3.2. Estimated creatinine clearance (eCCl)
The age, sex and weight of each subject were
determined. eCCls were calculated according to the
formulae as listed in Appendix A. Gender correction factors
were applied when indicated. If a formula estimated CCl per
1.73 m2 BSA, it was converted to the subject's BSA prior to
any analysis. Predictions were made without knowledge of
mCCl.
3.3. Statistical analysis
Results were expressed as the mean± the standard
deviation (S.D.). For each formula, mean eCCl and its S.
D., Pearson's correlation coefficient (r), p value, and bias
(mean eCCl−mean mCCl) was determined. Using meth-
ods described by Bland and Altman [24], 95% confidence
interval for bias and limits of agreement (LOA=bias±2 S.
D.) were computed. In the case of CGF and aMDRD,
these values were also calculated after splitting the data
by sex and the presence of renal insufficiency
(mCCl<80 ml/min). For the linear regression analysis,
mCCl was plotted on the x-axis vs eCCl on the y-axis
(Fig. 1). Data from non-CF controls were similarly
analysed.
To test the variability of the mCCls in subjects who
submitted more than one urine collection, a repeated measure
ANOVA model was devised, and an F test was used to
Fig. 1. (a) mCCl and eCCl correlation derived from the Cockroft–Gault formula in CF patients (r=0.69, P<0.001; mean bias 9.7 ml/min). (b) mCCl and eCCl
correlation derived from the Cockroft–Gault formula in non-CF controls (r=0.85, P<0.001; mean bias 3.4 ml/min). (c) mCCl and eCCl correlation derived from
aMDRD in CF patients (r=0.56, p<0.001; mean bias 4.9 ml/min). (d) mCCl and eCCl correlation derived from aMDRD in non-CF controls (r=0.88, P<0.001;
mean bias 1.4 ml/min).
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subjects.
4. Results
Table 2 lists the formulae in descending order of r value in
the CF group. Defining a better predictor as one with a
stronger correlation with the mCCl and a narrower range ofTable 2
Formulae derived eCCL (ml/min) and their relationship with mCCL in CF patient
Formula Mean eCCL (S.D.) r P
Agarwal 93.9 (21.9) 0.7 <0
Cronberg 95.2 (20.2) 0.7 <0
Mirahmadi 74 (16.1) 0.69 <0
CGF 92.6 (20.1) 0.69 <0
Jelliffe 2 87 (20.8) 0.67 <0
Lott 88.1 (19.3) 0.61 <0
MDRD (6 variable) 87.1 (19.2) 0.60 <0
Jelliffe 1 82.4 (14.9) 0.57 <0
aMDRD (4 variable) 88 (19.7) 0.56 <0
Salazar 106 (22.9) 0.55 <0error (LOA), CGF and either variety of MDRD were not
found to be superior to other formulae. Amongst formulae
with single digit bias in the CF group, CGF and Mirahmadi
had the narrowest LOA with CGF likely to overestimate
mCCl by as much as Mirahmadi likely to underestimate it.
As CGF and aMDRD are the most commonly used in
clinical practice, they were chosen for the further analyses
described below.s (mean mCCL (S.D.): 83.1 (22.9) ml/min)
value Bias 95% CI for bias LOA
.001 10.8 6.8 to 14.8 −23.6 to 45.2
.001 12.1 8.1 to 16.1 −21.7 to 45.9
.001 −9.1 −13 to 5.2 −42.3 to 24.1
.001 9.7 5.5 to 13.5 −24.9 to 43.9
.001 3.9 −0.2 to 8 −31.7 to 39.5
.001 5 0.6 to 9.4 −32.4 to 42.4
.001 4 −0.5 to 8.3 −34.3 to 42.3
.001 −0.7 −12 to 10.6 −38.1 to 36.7
.001 4.9 0.3 to 9.5 −35.3 to 45.1
.001 22.9 17.9 to 27.9 −20.7 to 66.5
Fig. 3. Percentage of eCCl results falling within 10%, 20% and 33% of
mCCl in CF patients and non-CF controls. CGF and aMDRD shown.
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subjects, the overall correlation was significant [r=0.69,
p<0.001 (Fig. 1)] but less solid than that in non-CF controls
[r=0.85, p<0.001]. Similar values were found for aMDRD
(0.56 and 0.88 respectively, p<0.001). Both formulae
generated greater mean bias (9.7 and 4.9 vs 3.4 and
1.4 ml/min respectively, p<0.05) and wider LOAs (−25 to
44 and −35.3 to 45.1 vs −24 to 31 and −23.6 to 26.4 ml/min
respectively) in CF patients compared with non-CF controls.
These are shown as Bland and Altman plots (Fig. 2).
Furthermore, CGF and aMDRD derived estimates within
10%, 20%, and 33% of mCCL for CF patients were only
25%, 54% and 78% and 27%, 56% and 77% respectively
compared with 35%, 72% and 95% and 62%, 85% and 97%
for controls (CGF: p<0.05 and <0.01; aMDRD <0.001 and
<0.01 at the 20% and 33% thresholds respectively) (Fig. 3).
MDRD produced similar results to aMDRD (data not
presented).
Thirty five CF patients had diminished mCCl compared
with 8 non-CF controls (47% vs 28%, p<0.01), and
significantly more mCCl readings were <80 ml/min in the
CF group (72 out of 159 (45%) vs 13 out of 60 (22%),
p<0.01). In our patients, both CGF and aMDRD grossly
overestimated CCl in the presence of renal insufficiency in
CF (Table 3): the bias was very large (18 and 16 ml/min
respectively) and the limits of agreement were wide (−10 to
46 and −18 to 50 respectively), considering that the mean
mCCl in this subgroup was only 63 ml/min. Conversely,
when mCCl was normal (≥80 ml/min), CGF and aMDRDFig. 2. Bland and Altman Plots comparing mCCl with CGF and aMDRD in
CF patients.were much more accurate predictors of CCl (mean bias 1.6
and −5.6 ml/min respectively, p<0.001). In contrast, both
formulae produced very similar results for both men and
women (Table 4). For the non-CF group, figures were similar
to overall CF data summarised in Tables 3 and 4 (data not
presented).
In both the CF and the control groups the first and
subsequent mCCl were not different from one another and
the intra-individual variation of repeat mCCl was similar in
both groups (P=NS for both groups, data not shown).
5. Discussion
With increasing reports of acute drug related renal injury
in CF patients, surveillance for aminoglycoside nephrotox-
icity is advocated [21,25]. How best to monitor renal
function in this patient group is unclear. Serum parameters
including creatinine and electrolyte levels, such as magne-
sium, are both insensitive and unreliable [26–29]. They may
remain within the normal range despite significant and
otherwise undetected loss of glomerular filtration. Indeed in
this study, all CF patients retained normal serum creatinine
concentrations despite 35 having subnormal mCCl.
Accurate measurement of glomerular filtration relies upon
a chemical that is merely filtered through the glomerulus,
without any active tubular reabsorption or secretion. Inulin is
such a compound, and its clearance is considered the “gold
standard” for measuring the glomerular filtration rate [7].
However, its use in day to day clinical medicine is
impractical. The use of the endogenous substance creatinine
(which has a constant and steady production from muscle
breakdown during periods of stable body weight and dietary
protein intake) is an acceptable alternative, although some
active secretion in the tubule may falsely elevate the
creatinine clearance rate above GFR by a factor of 1.1
[29]. This effect is exaggerated as GFR falls and the serum
creatinine rises [27,30,31]. Nevertheless, in clinical practice
Table 3
Comparison of mCCL and eCCL (CGF and abbreviated MDRD [4 variable]) in renally impaired CF patients (mCCL <80 ml/min)
n Mean mCCL (S.D.) eCCL formula Mean eCCL
(S.D.)
% eCCL within
33% of mCCL
Bias 95% CI for bias LOA
mCCL <80 35 63.5 (12.3) CGF 81.7 (18.1) 60% 18.3 13.6 to 23 −9.7 to 46.3
aMDRD 79.3 (20.2) 65% 15.8 10.5 to 22.0 −17.5 to 50.1
mCCL ≥80 39 100.7 (13.8) CGF 102.3 (16.6) 95% 1.6 −3.5 to 6.7 −30.4 to 33.6
aMDRD 95.1 (16.1) 84% −5.6 −11.1 to −0.1 −39.6 to 28.4
Total 74 83.1 (22.9) CGF 92.6 (20.1) 78% 9.7 5.5 to 13.5 −24.9 to 43.9
aMDRD 88 (19.7) 77% 4.9 0.3 to 9.5 −35.3 to 45.1
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inulin clearance to measure GFR. We therefore used this
method as the standard against which we judged formulae-
derived estimates. Although using it we showed that up to
40% of our patients had impaired renal function, the true
number with a diminished GFR is likely to be greater. We
were therefore assured that using this method did not
overestimate renal problems in our patients.
One possible criticism of this study is the use of timed
urine collection to derive creatinine clearance, where failure
to collect all urine in 24 h can result in an underestimate of
GFR. To avoid this, only specimens of adequate volume
(>500 ml) were included [8]. We could not find a published
reference range for normal daily creatinine excretion in adult
CF patients: to ensure that outlying creatinine values did not
bias the results, we only included samples within one
standard deviation of the mean value, of all pooled samples
per gender, for total 24-h creatinine excretion corrected for
body weight, a method used by other workers [23].
Additionally, thus labelled “valid” specimens generated
reproducible results on repeat measurement. We are
therefore confident that our technique for timed urine
collection allowed an accurate measurement of creatinine
clearance, in turn reflecting the GFR.
Nevertheless, this method of measuring creatinine
clearance in clinical practice is cumbersome; in adults
poor compliance can lead to collection errors and in
children collection may be difficult. In an attempt to
overcome this, several formulae [8–17] have been
developed that claim to approximate creatinine clearance
from serum creatinine concentrations by factoring in the
patient's biometric data with a range of constants. Recent
guidelines (K-DOQI [32] and UKCKDG [22]) suggest that
such formulae should be used to estimate GFR inTable 4
Gender based comparison of mCCL and eCCL (CGF and aMDRD) in CF patient
Sex n Mean mCCL
(S.D.)
eCCL formula Mean eCCL
(S.D.)
%
3
M 40 93 (21) CGF 103 (14) 8
aMDRD 97.8 (15) 7
F 34 72 (20) CGF 80 (19) 7
aMDRD 73.9 (17) 7
Total 74 83.1 (22.9) CGF 92.6 (20.1) 7
aMDRD 88 (19.7) 7preference to mCCL. All these formulae are predictors of
the measured CCl, and typically generate a range wherein
mCCl falls. The more accurate the formula, the smaller
this range: an ideal predictor should have a range equal to
zero and a correlation coefficient (r) equal to one. In
practice, however, all known formulae are associated with
some error, and the aim is to select a predictor that
correlates well with mCCl with the minimum of error.
Bland and Altman demonstrated that a positive correlation
does not always translate into a good prediction, nor does
a high r value alone guarantee an accurate prediction [24].
Instead, they described a more reliable way of comparing 2
methods of measuring a clinical variable [24]. They
documented the difference between the predicted value
and the measured value and devised limits of agreement
(mean difference±2 S.D.). Investigators can then decide if
this interval is acceptable within their clinical setting.
Using these definitions, the first 7 formulae in Table 2
could be equally applicable in CF patients, and none is
superior to the others.
We paid CGF and aMDRD particular attention since they
are the most commonly used formulae to estimate eCCl in
clinical practice. In their original monologue Cockroft and
Gault demonstrated an r=0.83, with 67% and 95% of their
predictions falling within 20% and 35% respectively of the
mCCl [8]. Other authors have reproduced similar results,
supporting the applicability of these formulae in several
disease groups [18–20,33–35] and the use of CGF in
assessing renal function in CF was recently recommended
[21]. In our series however, CGF derived eCCls compared
less favourably with those for non-CF controls with a lower
correlation (r=0.69 vs 0.85) with mCCl and a wider error
range (−25 to 44 vs −24 to 31). Additionally, significantly
fewer CF estimates fell within 20% and 33% of mCCl (54%s
eCCL within
3% of mCCL
r Bias 95% CI
for bias
LOA
0% 0.58 10 5 to 16 −16.6 to 38.2
4% 0.40 4.8 −0.4 to 10 −44 to 53.6
6% 0.58 8 2 to 14 −27.7 to 43.2
9% 0.62 1.9 −2.1 to 5.8 −32.7 to 36.5
8% 0.69 9.7 5.5 to 13.5 −24.9 to 43.9
7% 0.56 4.9 0.3 to 9.5 −35.3 to 45.1
46 M. Al-Aloul et al. / Journal of Cystic Fibrosis 6 (2007) 41–47vs 72% and 78% vs 95%, respectively). The results for
aMDRD were similar.
There are several possible explanations for the apparent
discrepancy between CGF and aMDRD accuracy in CF
patients compared with that in controls and other disease
groups.
Firstly, since serum creatinine is dependant upon muscle
mass, individuals with a diminished muscle mass may have
lower serum levels, resulting in a falsely high eCCl and
greater bias. This was shown in patients after spinal injury
[12], where paraplegia causes limited muscle mass relative to
body weight. The use of CGF in these patients was studied
by Mirahmadi et al. who found a large bias of 20 ml/min and
suggested a correction factor of 0.8 to account for this
overestimation. CF patients may similarly have a reduced
muscle mass compared with weight matched controls due to
their nutritional difficulties [36,37], a hyper catabolic state
from chronic systemic inflammation [38], and frequently a
limited exercise capacity [39]. Indeed, The formulas of
Cockroft and Gault, Jelliffe I and Jelliffe II all overpredicted
CrCl in a previous small study of 18 CF patients with biases
of 19, 24 and 8 ml/min and precisions of 37, 42 and 33 ml/
min respectively [40].
Secondly, it has been shown that formulae overestimate
creatinine clearance where there is renal impairment. For
example, in a study of the use of CGF in paraplegics by
Thakur et al., 30% of eCCls were outside 33% of mCCls in
the subgroup with renal impairment, and this has been
reproduced by other authors [23,41]. Thus, the significantly
higher proportion of urine collections generating subnormal
mCCl in our CF patient group than in the control group or in
Thakur et al.'s study (45% versus 22% and 18% respectively,
p<0.01) may have contributed to the overestimation
produced by CGF. With as many as 40% of eCCl falling
outside 33% of the corresponding mCCl for CGF (and 35%
for aMDRD) our results show that these formulae are less
accurate in predicting creatinine clearance in CF patients
with compromised renal function, the very group in which
this prediction is of greatest importance.
Thirdly, subtle differences in the renal physiology of CF
patients are known to exist but are not well understood [1]:
the enhanced drug clearance in the CF kidney [42] is one
such variation. It may be that one or more (as yet unknown)
variables or constants specific to the CF condition need to be
factored into such formulae in order to improve the
prediction accuracy.
The simplicity of their use makes such formulae attractive
tools in daily clinical practice, but they have one major
drawback: the formula is not reliable when serum creatinine
is unstable [8], thus overestimating GFR when serum
creatinine is rising and vice versa. Hence we ensured that
all subjects in this series were clinically well with stable renal
function. The lack of significant variability on repeat
measurement of creatinine clearance further supports this.
In summary, although CGF and aMDRD are as effective
as other formulae in estimating GFR in adult CF patients,their accuracy is limited and is not as robust as the traditional
timed urine collection method when carefully supervised.
Formulae have found a niche in calculating drug dosage in
renally impaired patients [43], and recent guidelines have
suggested that they are used in preference to timed urine
collections. However, in the context of regular surveillance
for aminoglycoside nephrotoxicity, we believe they should
be applied with caution as they may significantly overesti-
mate creatinine clearance and hence renal function in this
subgroup of CF patients; failing to identify the very patients
they are aiming to detect in clinical practice. As awareness of
drug related renal insufficiency in CF increases, so does the
need for a more accurate predictor of creatinine clearance in
these patients and based on our data we can not recommend
current formulae, including aMDRD and that described by
Cockroft and Gault, as an alternative to carefully supervised
direct measurement of creatinine clearance at the present
time.
Appendix A. Formulae for the estimation of CCl
reviewed in this studyAuthor(s) Male FemaleCockroft and Gault [8] (140−age)⁎
wt/72⁎SCr0.85⁎ formula for maleLott and Hayton [9] (140−age)⁎ lean
wt/72⁎SCr0.85⁎ formula for maleJellife [10] 98−0.8 (age−20)/SCr 0.9⁎ formula for male
Jellife [11] 100/SCr−12 80/SCr−8
Mirahmadi et al. [12] 0.8 (140−age)⁎
wt/72⁎SCr
0.85⁎ formula for maleAgarwal and Nicar [13] [28.2− (0.172⁎age)]⁎
wt/14.4⁎SCr[21.9− (0.115⁎age)]⁎
wt/14.4⁎SCrCronberg et al. [14] <70 kg: (170−age)⁎
wt/SCr(150−age)⁎wt/SCr>70 kg: (160−age)⁎
wt/SCrSalazar and Corcoran [15] [(146−age)⁎ (0.287⁎
wt+9.74⁎height2)]/
60⁎SCr[(137−age)⁎ (0.285⁎
wt+12.1⁎height2)]/
51⁎SCrMDRD (6 variable) 186⁎Scr−1.154⁎
age−0.203
0.742⁎ formula for maleAbbreviated MDRD
(4 variable)170⁎SCr⁎age−0.176⁎
SUrea−0.170⁎Alb0.318
0.762⁎ formula for maleReferences
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